Julie Dohm, J.D., Ph.D. was senior science advisor for compounding during a critical time and i am very sorry to see her leave the Agency. I had heard positive comments about her from some trusted friends before I heard her speak, but my own very positive personal impressions of her were formed at the 503B Listening Session last June. The two factors that so impressed me were that, when fielding questions from, and providing feedback to a frustrated audience, she
- …had the courage to “think out loud” from the podium about some tough and controversial issues; and
- …began her comments on more than one occasion by saying it’s vital for patients to have continued access to compounded drugs when FDA-approved agents don’t fit their needs.
She has an amazing combination of academic credentials, in the she has a Ph.D. in Structural Biology from Johns Hopkins, a Post-Doctoral Fellowship in Molecular Biophysics from Northwestern, a law degree from the University of Pennsylvania, and two law clerkship experiences in federal courts.
I wish her every success in her next chapter and I can only hope that her successor will be as trustworthy and committed to the value of compounding as I think she has been. Her last day at FDA will be March 29.